2019新型冠状病毒的研究进展  

Research Progress on SARS-CoV-2

作　　者：谢茜 伍政宇 舒跃龙 XIE Qian;WU Zhengyu;SHU Yuelong(School of Public Health(Shenzhen),Sun Yat⁃sen University,Guangzhou 510515,China)

机构地区：[1]中山大学公共卫生学院(深圳),广州510515

出　　处：《病毒学报》2020年第3期493-501,共9页Chinese Journal of Virology

基　　金：科技部重点研发计划项目新型冠状病毒感染的肺炎疫情应急(项目号:2020YFC0840900),题目:2019‐nCoV基因组变异规律和流行趋势预测研究。

摘　　要：自2019年12月以来,新型冠状病毒SARS-CoV-2引发的肺炎疫情在中国武汉暴发,随后疫情迅速蔓延,扩散至中国其它各省市。新型冠状病毒属于β冠状病毒属,与SARS-CoV和MERS-CoV近缘但有较大区别,尤其是刺突蛋白(Spike,S),根据序列相似性推断可能来源于蝙蝠,使用与SARS-CoV相同的血管紧张素转化酶Ⅱ(Angiotensin-converting enzymeⅡ,ACE2)受体进入细胞,以飞沫和接触传播为主要传播途径,缺乏有效药物治疗和疫苗是疫情防控的挑战。Since December 2019,the outbreak of coronavirus disease 2019(COVID-19)in Wuhan,China,has spread rapidly to other provinces and cities in China,and worldwide. Severe acute respiratory syndrome(SARS)-CoV-2 belongs to the β-coronavirus family,which is closely related to SARS-CoV and Middle East respiratory syndrome(MERS)-CoV,but quite different,especially in the spike protein. SARS-CoV-2 may be derived from bats according to sequence comparison. SARS-CoV-2 uses the same receptor,angiotensin converting enzyme Ⅱ(ACE2),as SARS-CoV. The main transmission routes include droplets and close contacts. The lack of effective drugs and vaccine is a challenge for outbreak control.

关 键 词：新型冠状病毒(SARS-CoV-2) 血管紧张素转化酶Ⅱ(ACE2) 病毒进化起源 

分 类 号：R373.1[医药卫生—病原生物学]